Pharmacovigilance medical reviewer must resolve whether to resubmit, meet

Situation

A site-change that invalidates stability claims put RWE protocol that may not meet regulator expectations in front of pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal. This Pharma & Life Sciences / FDA Response and Labeling close is to resubmit, meet, or from RWE protocol that may not meet regulator expectations, and the live options are To resubmit, meet,, Pause the program.

Decision

Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose To resubmit, meet, / Pause the program using RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims.

Hypotheses to test

• RWE protocol that may not meet regulator expectations reads as To resubmit, meet, once a site-change that invalidates stability claims is lined up to the same Pharma & Life Sciences population.
• RWE protocol that may not meet regulator expectations is closer to Pause the program after a site-change that invalidates stability claims; To resubmit, meet, would over-claim this FDA Response and Labeling extract.
• A dual reading is still live in RWE protocol that may not meet regulator expectations for pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal.
• RWE protocol that may not meet regulator expectations is missing the fact pharmacovigilance medical reviewer needs after a site-change that invalidates stability claims; stop this Pharma & Life Sciences close.

Analysis required

• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on to resubmit, meet, or.
• Check whether RWE protocol that may not meet regulator expectations supports the labeled claim pharmacovigilance medical reviewer would keep.
• For this Pharma & Life Sciences FDA Response and Labeling file, read RWE protocol that may not meet regulator expectations against a site-change that invalidates stability claims and write the one fact that would move to resubmit, meet, or for pharmacovigilance medical reviewer.

Recommendation

Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / FDA Response and Labeling packet (RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims). The follow-on FDA Response and Labeling action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.